



# BANDARAM PHARMA PACKTECH LIMITED

CIN:L93090KA1993PLC159827

BANDARAM PHARMA PACKTECH LIMITED													
[Formerly Known as Shiva Medicare Limited]													
CIN: L93090KA1993PLC159827													
Regd. Office: 601, 5th Floor, Oxford Towers, Opp. to Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore - 560008.													
Statement of Unaudited Results for the Quarter Ended and Three Months Ended 30.06.2022 (Amount Rs. in lakhs)													
S.No.	Particulars	STAND ALONE						CONSOLIDATED					
		For the Quarter ended			Three Months ended			For the Quarter ended			Three Months ended		
		30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	30.06.2022 (Unaudited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)	30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2022 (Unaudited)	30.06.2022 (Unaudited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
I	Revenue from Operations												
II	Other income												
III	Total income (I+II)												
IV	Expenses												
	(a) Cost of Materials consumed												
	(b) Purchase of stock-in-trade												
	(c) Changes in inventories of finished goods												
	(d) Employee benefits expenses	0.50			0.50								
	(e) Finance Cost		0.01				0.01	0.01			0.01	0.01	
	(f) Depreciation and amortisation												
	(h) Other expenses	11.94	1.00		11.94	1.00	17.10	1.00			17.10	1.00	
	Total Expenses	12.44	1.01		12.44	1.01	107.31	1.01			107.31	1.01	
V	Profit / (Loss) before and exceptional items and Tax (III-IV)	(12.44)	(1.01)		(12.44)	(1.01)	(16.69)	(1.01)			(16.69)	(1.01)	
VI	Exceptional items												
VII	Profit / (Loss) from before tax (V-VI)	(12.44)	(1.01)		(12.44)	(1.01)	(16.69)	(1.01)			(16.69)	(1.01)	
VIII	Tax expenses												
	Current Tax												
	Deferred Tax												
IX	Net Profit / (Loss) for the period from Continuing operations (VII-VIII)	(12.44)	(1.01)		(12.44)	(1.01)	(16.69)	(1.01)			(16.69)	(1.01)	
X	Profit / (Loss) from discontinuing operations												
XI	Profit / (Loss) from discontinuing operations after tax												
XIII	Profit/(loss) for the Period (IX+XII)	(12.44)	(1.01)		(12.44)	(1.01)	(16.69)	(1.01)			(16.69)	(1.01)	
XIV	Other Comprehensive Incomes												
A)	(i) Items that will not be recycled to profit or loss												
	(a) Others (gratuity and leave encashment excess provision reversal)												
	(ii) Income tax relating to items that will not be reclassified to profit or loss												
B)	(i) Items that may be reclassified to profit or loss												
	(ii) Income tax on items that may be reclassified to profit or loss												
	Total Comprehensive Income												
XV	Total Comprehensive Income for the	(12.44)	(1.01)		(12.44)	(1.01)	(16.69)	(1.01)			(16.69)	(1.01)	
XVI	Earnings Per Equity Share of face value of Rs.10/- each (for Continuing)												
	1) Basic	(0.41)	(0.03)		(0.41)	(0.03)	(0.56)	(0.03)			(0.56)	(0.03)	
	2) Diluted	(0.41)	(0.03)		(0.41)	(0.03)	(0.56)	(0.03)			(0.56)	(0.03)	
XVII	Earnings Per Equity Share of face value of Rs.10/- each (for Discontinuing)												
	1) Basic	(0.41)	(0.03)		(0.41)	(0.03)	(0.56)	(0.03)			(0.56)	(0.03)	
	2) Diluted	(0.41)	(0.03)		(0.41)	(0.03)	(0.56)	(0.03)			(0.56)	(0.03)	
XVIII	Earnings Per Equity Share of face value of Rs.10/- each (for Continued and Discontinuing operations)												
	1) Basic	(0.41)	(0.03)		(0.41)	(0.03)	(0.56)	(0.03)			(0.56)	(0.03)	
	2) Diluted	(0.41)	(0.03)		(0.41)	(0.03)	(0.56)	(0.03)			(0.56)	(0.03)	
XIX	Paid-up equity share capital (Face Value of Rs. 10/- per share)	300.00	300.00	227.70	300.00	227.70	300.00	300.00	227.70	300.00	227.70	300.00	

Notes:

- In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of the Companies Act, 2013, the above Financial Results have been prepared. The same is reviewed by the Statutory Auditors of Company and recommended by the Audit Committee and subsequently approved by the Board of Directors of Company at their meeting held on 22-07-2022.
- The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS-34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting pronouncements generally accepted in India.
- The figures of the previous year/periods have been re-grouped/re-classified, wherever necessary, for the purpose of comparison with the current year/period figures.
- The Company has no business operations during the quarter ending 30th June, 2022. Hence, segmentwise report as per Ind AS -108, is not applicable.
- The Company has acquired 55% shareholding in M/s. VSR Paper and Packaging Ltd., Hyderabad on 26-04-2022. Accordingly, this subsidiary company's quarterly results for the period ending 30th June, 2022, have been disclosed in this Financial Statements.
- The above Financial Results are also available on the company's website [www.bandaram.com](http://www.bandaram.com)

For and on Behalf of the Board of Directors  
Bandaram Pharma Packtech Limited  
(Formerly Known as Shiva Medicare Limited)

M. Munirahm Ruddy  
Managing Director  
CIN: L93090KA1993PLC159827

Place: Bangalore  
Date: 22.06.2022

Regd. & Corporate Office: Oxford Towers, Unit No. 601, 5th floor, Opp. to  
Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore-560008  
Ph No.: 9900002025 E-mail: info.bandaram@gmail.com